Home / Guidelines / Australian guidelines for biosimilars
Australian guidelines for biosimilars Posted 10/06/2011

Last update: 5 January 2018 The regulatory body for therapeutic goods in Australia is the Therapeutic Goods Administration (TGA).
TGA is a division of the Australian Government Department of Health and Ageing, and is responsible for regulating therapeutic goods including medicines, medical devices, blood and blood products. TGA administers the Therapeutic Goods Act 1989. This legislation provides a framework for a risk management approach that allows the Australian community to have timely access to therapeutic goods which are consistently safe, effective and of high quality. TGA carries out a range of assessment and monitoring activities to ensure therapeutic goods available in Australia are of an acceptable standard with the aim of ensuring that the Australian community has access, within a reasonable time, to therapeutic advances. In Australia, the European Union (EU) guidelines were adopted in August 2008 [1]. And on 30 July 2013, the TGA published its own guidance on the evaluation of biosimilars:
Evaluation of biosimilars In addition, Australia has adopted the following guidelines from the EU on similar biological medicinal products.
1. Overarching guidelines
Guideline on similar biological medicinal products CHMP/437/04 Rev 1
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: non-clinical and clinical issues EMEA/CHMP/BMWP/42832/2005 Rev1
2. Specific guidelines
Recombinant erythropoietins EMEA/CHMP/BMWP/94526/2005 Corr.
Revision of 2008. EMEA/CHMP/BMWP/301636/2008 not yet adopted by TGA.
Recombinant G-CSF EMEA/CHMP/BMWP/31329/200
Recombinant human insulin EMEA/CHMP/BMWP/32775/200
Low molecular weight heparins EMEA/CHMP/BMWP/118264/2007
Somatropin EMEA/CHMP/BMWP/94528/2005
Recombinant interferon alpha EMEA/CHMP/BMWP/102046/2006
3. Specific guidelines – not yet adopted
Monoclonal antibodies EMEA/CHMP/BMWP/403543/2010
4. Other guidelines
Immunogenicity assessment of biotechnology-derived therapeutic proteins
Comparability of Biotechnology-Derived Medicinal Products after a change in the Manufacturing Process - Non-Clinical and Clinical Issues
5. Other guidelines – not yet adopted
Immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use EMEA/CHMP/114720/2009
Related articles Global biosimilars guideline development – EGA’s perspective
Reference Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing. Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.
Effective date: 1 July 2013
http://www.tga.gov.au/industry/pm-argpm-biosimilars-00.htm
These guidelines cover all biosimilar products:
TGA Effective date: 22 May 2015
www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf
Under public consultation, effective date: 1 July 2015
TGA Effective date: 22 May 2015
www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf
These guidelines are specific to the type of biosimilar product:
Effective date: 29 September 2006
www.tga.gov.au/pdf/euguide/bmwp9452605en.pdf
Effective date: 1 October 2010
www.ema.europa.eu/docs/en_GB/document_library/ Scientific_guideline/2010/04/WC500089474.pdf
Effective date: 29 September 2006
www.tga.gov.au/pdf/euguide/bmwp3132905en.pdf
Effective date: 12 September 2006
www.tga.gov.au/pdf/euguide/emea3277505en.pdf
Effective date: 5 August 2009
www.tga.gov.au/pdf/euguide/bmwp11826407en.pdf
Effective date: 29 September 2006
www.tga.gov.au/pdf/euguide/bmwp9452805en.pdf
Effective date: 17 December 2010
www.tga.gov.au/pdf/euguide/chmp10204606enfin.pdf
TGA has the following guidelines published for information only for specific biosimilar products. These guidelines have not yet been adopted by the TGA.
Under public consultation, effective date: 1 December 2012
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf
Other guidelines relevant for biosimilars from the EMA include:
EMEA/CHMP/BMWP/14327/2006
Effective date: 22 June 2009
www.tga.gov.au/pdf/euguide/bmwp1432706en.pdf
CHMP/BMWP/101695/06
Effective date: 8 April 2009
www.tga.gov.au/pdf/euguide/bmwp10169506en.pdf
TGA has the following guidelines published for information only. These guidelines have not yet been adopted by the TGA.
Under public consultation, effective date: 15 July 2009
End of consultation: 28 May 2014
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf
Biosimilars approved in Australia
1. GaBI Online - Generics and Biosimilars Initiative. Global biosimilars guideline development – EGA’s perspective [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jan 5]. Available from: www.gabionline.net/Guidelines/Global-biosimilars-guideline-development-EGA-s-perspective
Source: TGA
Comments (0)
Generics News Research General
- Adherence improves long-term prognosis and medi...Generics/Research | Posted 19/02/2021
- Anti-competitive strategic patenting by pharmac...Generics/Research | Posted 12/02/2021
- Biocon and Lupin launch generic tacrolimus caps...Generics/News | Posted 05/02/2021
- New generics company to offer low-cost versions...Generics/General | Posted 29/01/2021
Biosimilars News Research General
- Improving stakeholder understanding about biosi...Biosimilars/Research | Posted 19/02/2021
- Canada approves infliximab biosimilar Remsima SCBiosimilars/News | Posted 19/02/2021
- Innovent starts phase II trial for ipilimumab c...Biosimilars/News | Posted 19/02/2021
- EMA recommends approval of adalimumab biosimila...Biosimilars/News | Posted 12/02/2021